Background:Psoriasis is a chronic disease with a multidimensional impact that extends beyond skin symptoms, affecting physical, emotional, social well-being and satisfaction with care. This study aims to explore the perceived self-reported impact of psoriasis on patients' well-being across different life stages and to identify risk and protective factors associated with well-being over time. Methods:A cross-sectional observational study was conducted using an electronic questionnaire administered to adult patients with psoriasis and healthcare professionals involved in psoriasis management. Patients retrospectively self-reported the perceived impact of psoriasis on overall well-being and its physical, emotional, social, and treatment-related domains across consecutive 10-year life stages. Both patients and healthcare professionals evaluated perceived risk and protective factors for well-being. Results:A total of 53 patients and 54 healthcare professionals completed the questionnaire. Most patients (90.6%) reported psoriasis had negatively affected their general well-being at some point during the disease course, with the physical (90.6%) and emotional (88.7%) domains being the most impacted. The highest perceived burden was reported between 31 and 40 years of age. Better reported symptom control was associated with lower perceived impairment in well-being. Key risk factors included affected body areas (95.3%), comorbidities (93.5%), and disease severity (89.7%), whereas appropriate treatment (96.3%), adequate medical care (93.5%), and a positive physician-patient relationship (89.7%) were identified as protective factors. Conclusion:These exploratory findings suggest that the self-reported perceived impact of psoriasis on well-being varies across life stages and is strongly influenced by symptom control and holistic disease management. These findings support a longitudinal, patient-centered approach to optimize long-term well-being.

INTRODUCTION:The Inpsight Project, established in 2021, aimed to define the concept of well-being in patients with psoriasis from a holistic perspective. Well-being was defined as a multi-dimensional concept that includes achieving emotional balance, having adequate overall health and control of the disease, enjoying positive social relationships, and being satisfied with disease care. However, while these components are recognized as integral to the concept, their relative contribution to achieving optimal well-being remains unclear. To address this gap, the present study aimed to determine the relative weight of each component in contributing to optimal well-being, focusing on a Spanish population. METHODS:An observational, descriptive, cross-sectional study was conducted in Spain using best-worst scaling (BWS). Two questionnaires were developed: one addressed to patients (33 item) and the other to healthcare professionals (HCPs) (18 item). The questionnaires collected sociodemographic and clinical (patients)/occupational (HCP) characteristics of the participants and the BWS scenarios. The 20 components of well-being were randomly distributed across 76 scenarios, with each component paired with others four times to ensure a comprehensive evaluation of all possible combinations. Participants assessed 9-10 randomly selected scenarios and identified the components they considered most (best) and least (worst) important for achieving optimal well-being. RESULTS:A total of 87 HCPs and 152 patients with psoriasis participated in the study. The five key components for patients were pain (P: 100.00), stress (P: 98.74), treatment satisfaction (92.21), itching (72.05), and lesions in functional locations (P: 69.09). From a HCP perspective, the most important components were mood disorders (100.00), pain (69.39), lesions in functional locations (49.34), self-esteem (49.24), and stigmatization/shame (45.22). CONCLUSIONS:This study highlights the differences between patients and HCPs in their perception of the relative importance and relevance of the components contributing to the well-being of patients with psoriasis. Future research should focus on understanding the cumulative impact of psoriasis on patient well-being.

INTRODUCTION:Integrated care pathways (ICPs) are crucial for delivering individualised care. However, the development of ICPs is challenging and must be well designed to provide the expected benefits. Regarding this, healthcare organisations are increasingly adopting management systems based on Lean Thinking to improve their organisational processes by eliminating non-value-added steps. This study elucidates the process and evaluates the impact of applying Lean Thinking to redesign an ICP for patients with spondyloarthritis, a chronic inflammatory disease affecting young adults. METHODS:A multidisciplinary team was assembled and trained in Lean Thinking. Patient's perspective was gathered through a focus group. Guided by an expert methodologist, the team constructed a value stream map of the entire care pathway and analysed each step. Five work streams were defined to increase value at each step, leading to targeted process improvements. Key process and outcome metrics were collected and compared in 2-month baseline and post-implementation audits. RESULTS:A total of 118 patients were included in the baseline audit (September-October 2022), and 116 in the post-implementation audit (January-February 2023). Process redesign resulted in statistically significant improvements (p < 0.05), including a reduction in the mean number of hospital visits per patient over a 2-month period from 2.54 (SD = 0.93) to 1.84 (SD = 0.79), an increase in complementary exams scheduled on the same day (81.4% to 94.8%) and an increase in baseline disease and treatment education (from 22.2% to 84.2% and from 18.2% to 84.6%, respectively). Regarding standardisation of clinical practice, there were significant increases in collecting data for medical records on composite activity indices (76.3% to 95.7%), reporting of pharmacological treatment adherence (68.6% to 94%) and providing nonpharmacological recommendations (31.3% to 95.7%). CONCLUSIONS:The application of Lean Thinking to redesign the spondyloarthritis ICP led to significant improvements in outpatient appointment scheduling, reduced patient hospital visits, improved interdepartmental coordination and standardised clinical practice.

Background: Primary Sjögren’s Syndrome (pSS) is a systemic autoimmune disease characterized by salivary gland involvement. Some patients may develop systemic extra glandular manifestations that can determine the prognosis of the disease. The influence of serological and immunological biomarkers on the clinical expression of the disease is still not fully known, nor is their role as prognostic factors of the disease. Objectives: The aim of the study was to assess the prevalence of extraglandular involvement in pSS, as well as to determine the relationship between immunological and serological biomarkers, disease activity, and extraglandular manifestations in patients with pSS. Methods: A cohort of patients with pSS who met the ACR/EULAR classification criteria for pSS in 2016 followed up in our Systemic Autoimmune Diseases Unit between 2000 and 2022 was carried out. The sociodemographic, clinical, serological and immunological data and the Disease activity measures calculated with the ESSDAI index (EULAR Sjögren’s Syndrome disease activity index) were collected. For the comparison of qualitative and/or quantitative variables, Fisher’s exact test or the T-test was performed when necessary. Results: 175 patients with pSS were included (85% were women), with a mean age at diagnosis of 58.8±12.2 years and a disease evolution time of 7.6±5.4 years. 62 patients (35%) had extraglandular manifestations. Anti-Ro60 positivity was found in 68%, Anti-Ro52 in 35.3% and anti-Ro60 and anti-La in 47.4% of patients. Associations between serological markers and systemic manifestations in patients with pSS is summarized in Graph 1 and Table 1. A higher risk of renal involvement was found in anti-Ro60, meanwhile a lung involvement, hypocomplementemia and higher levels of rheumatoid factor and hypergammaglobulinemia were associated with anti-Ro52 positivity. Constitutional symptoms, hematological involvement, lymphadenopathy, higher erythrocyte sedimentation rate and ESSDAI score were associated with both anti-Ro and anti-La positivity. Cutaneous involvement was specifically associated with anti-Ro52, C3 levels, IgG and IgM levels. Articular involvement was associated with higher rheumatoid factor levels. Renal involvement was associated with C3 levels, rheumatoid factor, ESR levels, IgG levels and anti-Ro60. Lung involvement was associated with ESR levels and C-reactive protein, IgG, C3 levels and anti-Ro52 positivity. CNS involvement was associated with C3 levels, C-reactive protein and beta2microglobulin and hematological involvement with C3, rheumatoid factor, beta2microglobulin and IgG levels. Conclusion: Our results have demonstrated the role of immunological and serological biomarkers in the clinical expression of pSS and as prognostic factors for disease progression, as well as their applicability in clinical practice. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: None declared.Graph 1Systemic manifestations accordingly to autoantibodies Table 1Associations between serological markers and systemic manifestations in patients with pSSC3C4RFESRCRPbeta2microglobulinIgGIgMAnti-Ro60Anti-LaAnti-Ro52Glandularp= 0.40p=0.91p= 0.06p=0.26p=0.69p=0.94p=0.55p= 0.92p=0.002p=0.04p=0.06Cutaneousp=0.003p=0.44p= 0.12p= 0.946p=0.85p=0.59p=0.03p=0.02p=0.23p=0.12p=0.04Articularp 0.23p 0.87p=0.003p=0.12p=0.23p=0.15p=0.06p=0.15p=0.34p=0.87p=0.32Renalp=0.04p=0.32p=0.007p=0.33p=0.53p=0.12p=0.033p=0.65p=0.40p=0.22p=0.45Lungp=0.03p=0.44p=0.45p=0.04p=0.001p=0.13p=0.02p=0.42p=0.26p=0.75p=0.02CNSp=0.04p=0.45p=0.62p=0.24p=0.12p=0.01p=0.39p=36p=0.52p=0.32p=0.14PNSP=0.62P=0.44P=0.64P=0.39P=0.38P=0.77P=0.55P=0.38P=0.42P=0.13P=0.92Hematologicalp=0.03p=0.179p=0.02p=0.01p=0.98p=0.001p=0.03p=0.22p=0.45p=0.45p=0.33Constitutionalp=0.003p=0.54p=0.21p=0.02p=0.94p=0.89p=0.21p=0.92p=0.42p=0.71p=0.23Lymphadenopathyp=0.19p=0.54p=0.02p=0.17p=0.8p=0.001p=0.49p=0.37p=0.78p=0.13p=0.35

Background: Interstitial lung disease (ILD) stands as the primary cause of mortality in patients with Systemic Sclerosis (SSc). Despite the identification of several risk factors to develop ILD in SSc, limited research has been directed towards understanding their impact on the progression of established SSc-ILD. Objectives: This study aims to evaluate the clinical characteristics of SSc patients with ILD and to compare features between those experiencing progressive lung function decline and those without such progression. Methods: We conducted a retrospective study on a cohort of 415 SSc patients. Inclusion criteria required the confirmation of ILD by HRCT. Demographic, clinical, analytical and pulmonary function tests (PFT's) parameters before and after ILD onset were collected. Statistical significance was set at p-values<0.05. Results: 64 patients with SSc-ILD were included, most of them females (93.8%) with a mean age at diagnosis of 60.5 years. Limited SSc was observed in 59.4%, and the predominant specific autoantibody was the anti-topoisomerase (28.1%). Table 1 summarizes the patient's characteristics. Follow-up revealed a significant decline in FVC in all patients since SSc onset (2.80±0.7 vs 2.16±0.76, p=0.000) and after ILD detection (2.37±0.69 vs 2.16±0.76, p=0.000). Male sex was associated with worse %FVC at SSc-ILD onset, persisting throughout follow-up and leading to poor lung function outcomes. However, no significant differences were found in FVC decline based on clinical SSc subset (limited vs. diffuse) or SSc autoantibodies (ATA vs. ACA) after ILD onset. Smoking history, digital ulcers, and pulmonary hypertension were associated with poor lung function outcomes. No significant differences were observed in other clinical features such as myositis, arthritis, gastrointestinal involvement, renal crisis, or cancer. Rheumatoid factor (RF) positivity was associated with poorer pulmonary function after ILD diagnosis (p=0.034). The presence of a UIP pattern did not correlate with worse lung function at the onset of ILD or at follow-up, when compared to non-UIP patterns. Among the twenty-four patients who received ILD treatment, both %FVC and ml-FVC outcomes worsened, with no significant differences noted in DLCO. Conclusion: Worse lung function outcomes after SSc-ILD onset were associated to male sex, smoking history, digital ulcers, pulmonary hypertension, and RF positivity. Notably, in contrast to patients at risk of developing SSc-ILD, no significant differences were observed based on SSc subset or SSc autoantibodies in patients with established ILD. Early volume decline was observed during follow-up, even before ILD onset, in all patients within our cohort. We did not find that treatment prevents pulmonary function decline. It could be explained by the inclusion of patients with unfavorable prognosis factors and the retrospective nature of the analysis. Prospective, multicentric studies to comprehensively assess risk factors for poor prognosis and the progression SSc-ILD patients are needed. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: None declared.

Background: Juvenile Idiopathic Arthritis (JIA) represents the most prevalent inflammatory rheumatic condition in childhood. Its heterogeneous nature presents challenges in identifying feasible biomarkers for effective disease monitoring. Serum calprotectin (sCal) has emerged as a potentially valuable biomarker for precisely assessing inflammatory activity in JIA. Despite various commercially available methods for sCal determination, their usage remains limited and lacks validation. Objectives: To assess the diagnostic accuracy, define an optimal threshold, and evaluate the association between disease activity status in patients with JIA and serum calprotectin measurements obtained through chemiluminescence (CLIA) and solid-phase enzyme immunoassay (EIA) techniques within a real-world clinical setting. Methods: Serum samples from 25 pediatric patients with JIA were analyzed. sCal levels were determined by CLIA and EIA methodologies. Disease activity data was collected through JADAS-27 and the Anink ACR-modified criteria (1). We conducted a comparative analysis of results obtained through CLIA and EIA techniques. Additionally, we assessed the association between distinct biomarkers and disease activity. Results: The tests demonstrated robust performance of sCal. The ideal cut-off value for sCal in identifying disease activity, as determined by ROC analysis related to JADAS-27, was 2.3 µg/mL for both CLIA and EIA techniques. Remarkably, this value aligned with the threshold routinely utilized in our center's daily clinical practice. When evaluating disease activity based on Anink's criteria, the identified optimal thresholds were 2.0 µg/mL for sCal CLIA and 2.9 µg/mL for sCal EIA. Notably, the sCal CLIA identified threshold (2.0 µg/mL) coincided with the one recommended by its commercial kit. In contrast, the thresholds proposed for CRP and ESR (3.1 mg/L and 10 mm/h, respectively), according to both JADAS-27 and Anink, were lower than the values routinely employed in daily clinical practice (5 mg/L for CRP and 20 mm/h for ESR). A good correlation was observed between sCal levels obtained by CLIA and EIA Kendall's tau-b 0.71, p<0.001). The sensitivity of sCal outperformed the conventional inflammatory biomarkers CRP and ESR, exhibiting superior accuracy in distinguishing patients with active disease. In our cohort, a notable case involved an active patient experiencing concurrent arthritis and uveitis during data collection, exhibiting a significant discrepancy in biomarker measurements showing elevated sCal levels (≥2.3µg/ml) but without a corresponding increase in CRP or ESR. However, sCal showed reduced specificity compared to CRP and ESR, resulting in the conventional biomarkers proving more effective in identifying patients in a state of remission. Conclusion: Serum calprotectin, determined through CLIA and EIA, emerges as a valuable biomarker for monitoring disease activity in patients with JIA. It exhibits good sensitivity for identifying active patients at its cutoff point of 2.3 µg/mL, especially through EIA. The results suggest sCal is superior for identifying activity, while CRP and ESR excel in distinguishing remission. The combined use of various serum biomarkers could enhance the precision of disease activity assessment in JIA. REFERENCES: [1] Anink J, Van Suijlekom-Smit LW, Otten MH, Prince FH, van Rossum MA, Dolman KM, et al. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis research & therapy. 2015;17(1):200 Acknowledgements: NIL. Disclosure of Interests: None declared.

Atopic dermatitis is a cutaneous inflammatory disease characterized by intense pruritus, which is often underestimated despite its direct impact on patients’ health-related quality of life and the high burden it poses. The authors’ goal was to design a qualitative tool to guide patients and healthcare professionals in their assessment and interpretation of pruritus intensity using a numerical rating scale. The draft of this tool, henceforth “guideline”, was developed based on a systematic literature review and focus groups comprising patients and a scientific committee. This draft was validated with an independent group of patients and the final version was designed following their feedback. According to the results of the systematic review, pruritus impacts 6 health-related quality of life domains: sleep quality; emotional status; overall health-related quality of life; physical function; social/sexual activity; productivity, particularly affecting sleep quality and the emotional domain. Patients considered that physical function was the most strongly affected domain, followed by sleep quality and emotional well-being, establishing that a minimum pruritus intensity of 4 and 7 points impacts moderately and severely, respectively, on the different domains of patients’ health- related quality of life. The guideline may help patients and healthcare professionals to interpret and assess pruritus intensity using a numerical rating scale and to understand the impact of pruritus on patients’ health-related quality of life.

Background: Activity indices in Systemic Lupus Erythematosus (SLE) are tools to assess disease severity, guide treatment decisions, and evaluate treatment response. The commonly used SLEDAI-2K has been recently joined by SLE-DAS. “Treat to target” strategies have gained importance, aiming for remission or low disease activity, defining Lupus Low Disease Activity State (LLDAS) and DORIS2021 remission. Objectives: To assess the relationship between SLEDAI-2K and SLE-DAS and the definition of low disease activity (LLDAS) and remission (DORIS2021) in SLE. Methods: A retrospective descriptive cross-sectional study was conducted in a cohort of patients diagnosed with SLE, visited between September 2022 and November 2023 at a tertiary hospital. Patients had to meet EULAR/ACR 2019 Classification Criteria at some point during their disease course. Demographic, clinical, analytical, and index variables were collected. Analysis of variables was performed using Spearman’s correlation coefficient and Mann-Whitney U test. Statistical significance was set at p<0.05. Results: A total of 57 patients were included (94.7% females, mean age 48.5 years, mean disease duration 13.08 years). Common manifestations included arthralgia (35.1%) and arthritis (12.3%). Less frequent were cutaneous involvement (7%) and oral mucosal ulcerations (3.5%). No cases of serositis, fever, or myositis were observed. Urinary sediment abnormalities were present in 28.1% of patients, and 7% had significant proteinuria. Only 1 patient experienced a renal flare. Serologically, 36.8% had elevated DNA levels, and 36.8% had low C3 and/or C4 levels.Table 1 displays values and relationships between SLEDAI-2K and SLE-DAS by activity. No patients had severe SLEDAI-2K (>10). The correlation between the two indices was good (Spearman’s coefficient 0.786, p<0.001). However, when variables were categorized (remission, mild, moderate, severe), the relationship disappeared (kappa coefficient 0.186, p=0.064). In our cohort, 71.9% of patients were in remission according to SLE-DAS, and 35.1% according to SLEDAI-2K.Additionally, 78.9% and 68.4% of patients met LLDAS and DORIS2021 criteria, respectively. Table 2 shows relationships between each activity index and LLDAS and DORIS2021. Both SLEDAI-2K and SLE-DAS were significantly associated with LLDAS (p=0.006 and p<0.001, respectively) and DORIS2021 (p=0.018 and p<0.001, respectively). Conclusion: A significant correlation exists between SLEDAI-2K and SLE-DAS, but it loses significance when variables are categorized. This is attributed to substantial divergence in remission and low activity categories between the two indices. With the exception of one patient (1.8%) in SLEDAI-2K remission, all others meet remission criteria by SLE-DAS. However, many patients in SLE-DAS remission exhibit mild activity in SLEDAI-2K, mainly due to serological manifestations. Both indices show a significant association with LLDAS and DORIS2021, despite SLE-DAS not being part of their definitions. Notably, the proportion of patients in remission by SLE-DAS aligns more closely with the proportions of LLDAS and DORIS2021 than SLEDAI-2K. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: None declared.Table 1SLE-DAS remission (≤2.8)n (%)SLE-DAS mild (2,09-7.64)n (%)SLE-DAS moderate/severe(≥7.65)n (%)Totaln (%)SLEDAI2K remission (=0)n (%)19 (33.3)1 (1.8)020 (35.1)SLEDAI2K mild (1-5)n (%)22 (38.6)7 (12.3)3 (5.3)32 (56.1)SLEDAI2K moderate (6-10)n (%)04 (7)1 (1.8)5 (8.8)Totaln (%)41 (71.9)12 (21.2)4 (7)57 (100) Table 2MedianSLEDAI-2KSLEDAI-2K remission n (%)SLEDAI-2K mild n (%)SLEDAI-2K moderate n (%)LLDAS not met3.831 (1.8)6 (10.5)5 (8.8)LLDAS met1.6919 (33.3)26 (45.6)0DORIS2021 not met3.223 (5.3)10 (17.5)5 (8.8)DORIS2021 met1.6417 (29.8)22 (38.6)0Median SLE-DASSLE-DAS remissionn (%)SLE-DAS mildn (%)SLE-DAS moderate/severen (%)LLDAS not met5.252 (3.5)8 (14)2 (3.5)LLDAS met1.6639 (68.4)4 (7)2 (3.5)DORIS2021 not met4.405 (8.8)11 (19.3)2 (3.5)DORIS2021 met1.536 (63.2)1 (1.8)2 (3.5)

Psoriasis is a chronic skin disease that negatively impacts on patient’s life. A holistic approach integrating well-being assessment could improve disease management. Since a consensus definition of well-being in psoriasis is not available, we aim to achieve a multidisciplinary consensus on well-being definition and its components. A literature review and consultation with psoriasis patients facilitated the design of a two-round Delphi questionnaire targeting healthcare professionals and psoriasis patients. A total of 261 panellists (65.1% patients with psoriasis, 34.9% healthcare professionals) agreed on the dimensions and components that should integrate the concept of well-being: emotional dimension (78.9%) [stress (83.9%), mood disturbance (85.1%), body image (83.9%), stigma/shame (75.1%), self-esteem (77.4%) and coping/resilience (81.2%)], physical dimension (82.0%) [sleep quality (81.6%), pain/discomfort (80.8%), itching (83.5%), extracutaneous manifestations (82.8%), lesions in visible areas (84.3%), lesions in functional areas (85.8%), and sex life (78.2%)], social dimension (79.5%) [social relationships (80.8%), leisure/recreational activities (80.3%), support from family/friends (76.6%) and work/academic life (76.5%)], and satisfaction with disease management (78.5%) [treatment (78.2%), information received (75.6%) and medical care provided by the dermatologist (80.1%)]. This well-being definition reflects patients’ needs and concerns. Therefore, addressing them in psoriasis will optimise management, contributing to better outcomes and restoring normalcy to the patient’s life.

Introducciónla psoriasis es una enfermedad crónica que afecta la calidad de vida y el bienestar de los pacientes y su abordaje debe contar con su participación. El objetivo de este estudio fue conocer la percepción de personas con psoriasis en España sobre la gestión emocional de la enfermedad, detectar las necesidades no cubiertas e identificar estrategias para paliar sus consecuencias en la salud emocional.Material y métodosun cuestionario elaborado por un grupo multidisciplinar fue enviado por la asociación Acción Psoriasis a sus socios entre noviembre y diciembre de 2021. Este cuestionario autoadministrado abordó aspectos de salud emocional y reproductiva, implicaciones sociolaborales y utilización de recursos relacionados con la atención emocional y psicológica de la psoriasis. Se realizó un análisis descriptivo de las respuestas recogidas.Resultadosse analizaron 746 cuestionarios (69,6% mujeres; edad mediana 46 años). Los pacientes consideraron que la psoriasis afectó a su estado de ánimo (87,1%), a su carácter (71,2%), a su autoestima (74,9%) y su vida social (52,1%). Al 75,6% le causó ansiedad, al 75,9% tristeza/depresión, al 78,1% estrés, al 71,1% alteraciones del sueño. El 59,5% consideró no tener suficiente información sobre la atención o la gestión emocional de la psoriasis. El 73,6% contestó no haber recibido ningún material informativo sobre la psoriasis y 86,2% no haber recibido recomendaciones sobre cómo abordar su malestar emocional.Conclusionesen general, los pacientes consideraron que la repercusión de la psoriasis en su bienestar y calidad de vida no se tuvo suficientemente en cuenta por parte de los profesionales sanitarios.

Background: Primary Sjögren's Syndrome (pSS) is a systemic autoimmune disease characterized by salivary gland involvement. Some patients may develop systemic extra glandular manifestations that can determine the prognosis of the disease. The influence of serological and immunological biomarkers on the clinical expression of the disease is still not fully known, nor is their role as prognostic factors of the disease. Objectives: The aim of the study was to assess the prevalence of extraglandular involvement in pSS, as well as to determine the relationship between immunological and serological biomarkers, disease activity, and extraglandular manifestations in patients with pSS. Methods: A cohort of patients with pSS who met the ACR/EULAR classification criteria for pSS in 2016 followed up in our Systemic Autoimmune Diseases Unit between 2000 and 2022 was carried out. The sociodemographic, clinical, serological and immunological data and the Disease activity measures calculated with the ESSDAI index (EULAR Sjögren's Syndrome disease activity index) were collected. For the comparison of qualitative and/or quantitative variables, Fisher's exact test or the T-test was performed when necessary. Results: 175 patients with pSS were included (85% were women), with a mean age at diagnosis of 58.8±12.2 years and a disease evolution time of 7.6±5.4 years. 62 patients (35%) had extraglandular manifestations. Anti-Ro60 positivity was found in 68%, Anti-Ro52 in 35.3% and anti-Ro60 and anti-La in 47.4% of patients. Associations between serological markers and systemic manifestations in patients with pSS is summarized in Graph 1 and Table 1. A higher risk of renal involvement was found in anti-Ro60, meanwhile a lung involvement, hypocomplementemia and higher levels of rheumatoid factor and hypergammaglobulinemia were associated with anti-Ro52 positivity. Constitutional symptoms, hematological involvement, lymphadenopathy, higher erythrocyte sedimentation rate and ESSDAI score were associated with both anti-Ro and anti-La positivity. Cutaneous involvement was specifically associated with anti-Ro52, C3 levels, IgG and IgM levels. Articular involvement was associated with higher rheumatoid factor levels. Renal involvement was associated with C3 levels, rheumatoid factor, ESR levels, IgG levels and anti-Ro60. Lung involvement was associated with ESR levels and C-reactive protein, IgG, C3 levels and anti-Ro52 positivity. CNS involvement was associated with C3 levels, C-reactive protein and beta2microglobulin and hematological involvement with C3, rheumatoid factor, beta2microglobulin and IgG levels. Conclusion: Our results have demonstrated the role of immunological and serological biomarkers in the clinical expression of pSS and as prognostic factors for disease progression, as well as their applicability in clinical practice. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: None declared.

Background The most important diagnostic test in Sjogren’s syndrome is the minor salivary gland test (MSGB). Immunohistochemical staining of the MSGB may provide prognostic value for organ affection. Objectives To compare the lymphocytic composition of the MSGB and major organ affection in patients with Sjogren’s syndrome during 3 years of follow-up. To compare the lymphocytic composition of the MSGB and worsening of SSDDI index more than 2 points. Methods A retrospective cohort study was conducted. Inclusion criteria was patients ≥18 years that met 2016 ACR/EULAR criteria for Sjogren’s Syndrome with focal lymphocytic sialadenitis (≥1 infiltration of ≥50 lymphocytes) by MSGB. CD45, CD4, CD8, CD20 staining was carried out for all samples. Infection, amyloidosis, IgG4 related diseases or head radiation therapy were excluded. Finally, 78 patients from the systemic autoimmune diseases division between September 2017 – October 2018 were included. Patients were followed up for 3 years. The outcomes evaluated were: 1. Severe organ affection (defined as lymphoma, interstitial lung disease, central or peripheral nerve system, renal involvement or arthritis) that required steroids or disease modifying drugs; 2. Worsening of SSDDI index ≥ 2 points. Results The mean age was 60.6 (SD 12.7) and 8 (10.3%) of the patients were men. There was overlap with other SAD in 13 (16.7%) patients. Severe organ damage was present in 16 (20.5%) and moderate or high ESSDAI in 6 (7.7%) at baseline. Ro52/60 was present in 15 (19.3%). Steroid treatment was used in 6 (7.8%). The baseline characteristics of patients with severe organ affection was compared with patients that did not present severe organ affection. Patients with severe organ affection had a significantly higher proportion of male sex (56.3% vs 35.7%), higher median baseline ESSDAI (3.81 vs 1.06, p=0.00) and SSDDI (1.88 vs 1.02, p=0.04). Higher proportion of lymphoma (18.8% vs 3.2%, p=0.024), higher proportion of steroids (37.5% vs 0, p=0.00) and higher proportion of disease modifying drugs (37.5% vs 3.2%, p=0.00) were observed as well. The comparison of lymphocytic composition of the BGSM according to outome 1 and outcome 2 are summarized in Table 1. Conclusion There were significantly increased number of total lymphocytes and number of infiltrates in the MSGB of patients that presented severe organ affection within 3 years of follow up. Also a significantly increased number of T cells, both CD4+ and CD8 cells, were observed in patients with severe organ affection. Reference [1] Clin Immunol 182, 48-53 (2017) Acknowledgements: NIL. Disclosure of Interests None Declared.

Background Little is known about the chronologic order of appearance of extra-articular symptoms and spondylarthritis (SpA) symptoms and its effect in disease progression. Most information is based on population-based registries or big data that may lack precision. Objectives To describe duration, time until diagnosis and order of appearance of the articular and extra-articular (psoriasis, uveitis, or inflammatory bowel disease) symptoms.To evaluate factors associated with time from extra-articular symptoms onset until appearance of SpA symptoms. Methods A retrospective cohort study was conducted. Inclusion criteria were patients that met ASAS criteria visited at the SpA clinic between July – October 2022. Other autoimmune rheumatic diseases were excluded. Data were collected previously reviewing patient records available from the electronic and paper database of the hospital. Additional information was retrieved by the shared medical history database of the Catalan Institute of Health which attends the 99.2% of the population. Missing data were collected prospectively by patient interview. Univariate linear regression was conducted to study association. Results From 91 patients 54 (59.3%) were male and mean age was 63.9 (SD 14.3). There were 46 (50.5%) patients with exclusively peripheral SpA and 17 (16.5%) exclusively axial SpA. History of extraarticular symptoms were observed in 69 (76.6%) of the patients and 33 (37.1%) were HLA-B27 positive. In 49 (54.8%) patients extra-articular symptoms appeared before SpA.The median disease duration since SpA diagnosis was 11 year (IQR 14). Median time for SpA diagnosis since articular symptoms onset was 2 years (IQR 8).The median time from the extra-articular symptoms until the appearance of articular symptoms was 2 years (IQR 30). The associations of SpA features and time since first extra-articular symptoms until articular symptoms appearance is detailed in table 1. HLA-B27 positivity and axial disease showed a negative linear association while peripheral disease showed a positive linear association. Conclusion Most patients presented extra-articular manifestation before articular symptoms onset.The median delay since first articular symptoms until SpA diagnosis was 2 years.Longer time between extra-articular manifestation and articular symptoms was liniarly associated with peripheral disease.Axial disease and HLA-B27 were linearly associated with shorter time between the two symptoms. Reference [1]Rheumatol 2021;60(6):2725-2734. Acknowledgements: NIL. Disclosure of Interests None Declared.Table 1VariablesCoef (p)Age (year)0.15 (0.42)Male0.65 (0.91)Smoker-2.31 (0.54)B27 positivity-21.4 (0.00)Elevate CRP-1.16 (0.86)Erosions1.97 (0.77)Radiographic sacroiliitis-4.43 (0.24)Peripheral SpA16 (0.03)Axial SpA-23.8 (0.01)Peripheral and Axial-13 (0.02)

Background Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired muscle diseases, which have distinct clinical, pathological and histological features. Autoantibodies are clinically useful biomarkers to help the diagnosis of IIM. Raynaud's phenomenon is very frequent and the presence of microvascular changes in IIM have been described however, the role of nailfold videocapillaroscopy NVC) for diagnosis and prognosis in IIM is not clearly established. Objectives The aim of this study was to study the relationship between clinical and immunological characteristics and nailfold videocapillaroscopy (NVC) abnormalities in patients with idiopathic inflammatory myopathies (IIMs). Methods We performed a retrospective study of IIM patients followed in a University Hospital. Patients underwent a NVC at 200x magnification. Epidemiological, clinical data and antibody status, including myositis and scleroderma antibody panel of all patients was retrieved. NVC findings including loss of capillary density, enlarged and giant capillaries, ramified capillaries, haemorrhages, thrombosis, avascular areas, disorganization of capillary architecture and subpapillary venous plexus presence were recollected, if present. For the comparison of qualitative and/or quantitative variables Fisher's exact Test or T-test was performed when necessary. Results 95 patients with NVC performed during the follow-up were included (66% female) with a median age at inclusion of 55.3±24 years. Median IIM duration was 6.8±7 years. 39% had Raynaud's phenomenon at first clinical evaluation and 58% of them showed NVC pathological findings. Table 1 Summarizes the epidemiological, clinical, and autoantibody status of the patients. We found an association between the presence of dysphagia and avascular areas (p=0.02) or abnormal capillary organization (p<0.01) on NVC. ILD was associated with capillary loss (p=0.04) and avascular areas (p=0.004). Anti-MDA5+ was associated with capillary loss (p=0.03), thrombosis (p=0.02) and ramified capillaries (p=0.04). Anti-Mi2+ and anti-Th/To was associated with abnormal capillary organization (p=0.017 and p=0.001). The presence of haemorrhages was associated with anti-Ku+ (p=0.048) and anti-PL12+ (p=0.046). The presence of enlarged capillaries was associated with anti-RNA-pol III (p=0.04) and anti-NXP2 (p=0.044). A significant association between anti-Ro52 (OR 2.69, CI 95% 1.05-6.8, p 0.03) and anti-Jo1 (OR 7.03 CI 95% 1.46-33.7, p 0.01) with ILD was found. Anti-PML (OR 4.32 CI 95% 1.35-10.42, p 0.038) and anti-Th/To (OR 5.82 CI 95% 1.89-13.24, p 0.04) were associated with dysphagia. Anti-MDA5 (OR 5.85 CI 95% 1.92-14.21, p 0.044) was associated with skin involvement. Conclusion The presence of certain autoantibodies is related to the degree of microangiopathy in IIM and associates with capillaroscopic changes. Studying the association between capillaroscopic changes with diagnostic and pathogenic autoantibodies in IIM can provide useful information regarding the current knowledge about pathogenesis, classification, and prognosis of the disease. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests None Declared.Table 1: Epidemiological, clinical, immunological and NFC features and autoantibody status from patients with IIMClinical featuresMuscle weakness79 (83%)Skin findings30 (32%)ILD47 (49%)Dysphagia18 (19%)Raynaud's phenomenon37 (39%)CK elevation45 (47%)Cardiac disease4 (4%)NFC featuresLoss of capillary density27 (28%)Enlarged and giant capillaries37 (39%)Haemorrhages36 (38%)Thrombosis19 (20%)Avascular areas26 (27%)Disorganization of capillary architecture24 (25%)Subpapillary venous plexus36 (38%)Antibody statusDisease-specific antibodiesAnti-MDA58 (8%)Anti-TIF1G11 (12%)Anti-MI211 (12%)Anti-NXP26 (6%)Anti-synthetase antibodiesAnti-Jo113 (14%)Anti-PL79 (9%)Anti-PL125 (5%)Disease-associated antibodiesAnti-Ro5227 (28%)Anti-KU6 (6%)Antinuclear antibodiesOthers (EJ, SRP, PM-SCL75, PM-SCL100, CN1A)61 (64%)22 (23%)

Background Pregnancy in patients with systemic lupus erythematosus (SLE) are known to be at high risk for the occurrence of adverse pregnancy outcomes. Pre-conception counselling and risk stratification performed in a multidisciplinary clinical setting with rheumatologists, obstetricians and nephrologists are essential for improving pregnancy outcomes and reducing maternal and perinatal complications in patients with SLE. Objectives To describe clinical, obstetric and maternal comorbidities and pregnancy in patients with SLE and patients with other systemic autoimmune diseases (SADs). Methods A retrospective cohort study was conducted including patients diagnosed with SLE attending our multidisciplinary pregnancy clinic. Clinical, immunological and obstetric variables were collected. Data related to pregnancy outcomes, delivery and disease activity were also collected. Description of the sample and comparison of groups were carried out. Shapiro-Wilk test was used for variable distribution. Results A total of 41 patients attended our outpatient preconception clinic. Comparison and description of the comorbidities, preconception counseling and pregnancy outcomes are summarized in Table 1. A total of 19 (43.2%) patients were diagnosed with SLE. Lupus nephritis was observed in 47% of the patients and 11% had received kidney transplant. Moderate SLEDAI activity (>4) was observed in 44.4%. There were 7 (37%) pregnancies after a mean time of 7.3±6 months since the first visit. SLE patients were significantly older when evaluated at the pregnancy clinic than patients with other SADs. Also, SLE patients exhibited a longer time since the last flare when evaluated at the pregnancy clinic. Significant differences were observed in treatment between both groups: more hydroxychloroquine, synthetic DMARDs and steroids were used in the SLE group. No significant differences in preconception counseling or adverse pregnancy outcomes were observed. Conclusion Patients with SLE took longer time since diagnosis and flare to seek pregnancy than patients with other SAD. No differences in pregnancy outcomes or risk profile were observed. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests None Declared.Table 1SLE (n=19)Non-SLE (n=22)P valueSociodemographic dataAge at visit (year)Age at diagnosis (year)Diagnosis-1st visit (years)Last flare-1st visit (months)36.8±4.6124.7±9.69.78±5.9548±41.7634.4±3.9331.7±6.75.09±6.0919.4±32.50.080.02 0.004 0.01Before preconception counselling Abortion (n, %)Preterm (n, %)Low-weight at birth (n%)6 (33.3)5 (71.43)2 (28.5)7 (45.75)000.9870.060.239Treatment, n (%)- c/tsDMARD - HCQ- bDMARDs8 (42.1)8 (26.3)2 (26.3)3 (13.64)3 (13.64)9 (40.41)0.049 0.049 0.04Glucocorticoids (n, %)Previous CYC (n, %)14 (73.7)5 (26.3)7 (31.82)00.0090.06Pregnancy risk (n, %)- Low - Moderate - High8 (42.1)8 (42.1)3 (15.8)13 (59.1)8 (36.4)1 (4.55)0.280.710.25After preconception counselling Assessment (n, %)- Fit to conception- Not fit to conception- Fit to conception after treatment change- Pregnant at 1st visit7 (36.8)6 (31.58)3 (15.8)3 (15.8)12 (54.6)4 (18.2)2 (9.1)4 (18.2)0.260.320.520.83Complications in pregnancy (n,%):- Medical- Obstetrical2 (15.5)003 (10.7)0.24Abortion (n, %)Preterm (n, %)Low weight at birth (n, %)1 (7.69)2 (10.5)2 (10.5)0000.440.240.24

Background Pre-conception counselling and risk stratification performed in a multidisciplinary clinical setting with rheumatologists, obstetricians and nephrologists may improve pregnancy outcomes in systemic autoimmune disease (SAD). Objectives To compare clinical, obstetrical comorbidities and pregnancy outcomes in patients with SAD with history of pregnancy loss with patients without history of pregnancy loss. Methods A retrospective cohort study was conducted. A total of 41 patients with SADs that attended the multidisciplinary preconception outpatient clinic were included. Variables related to SADs, obstetric comorbidities and pregnancy outcomes were collected. Description of the sample and comparison of groups were carried out. Shapiro-Wilk test was used to study normality. Results The description and comparison of the comorbidities, preconception counselling and pregnancy outcomes are summarized in Table 1. A total of 18 (46%) patients had a history of pregnancy loss. Fewer patients with history of pregnancy loss, 38.5% were fit for conception compared to 54.3% of patients with a history of pregnancy loss. Deferment of pregnancy was advised for 38.5% of patients with history of pregnancy loss and 54.3% in patients without history of pregnancy loss. Patients with a history of pregnancy loss had significantly higher anti-DNAds, antiphospholipid positivity and longer time since last flare.There was no significant difference for adverse pregnancy outcomes, disease activity or treatment. Interestingly, the distribution of risk profile for adverse pregnancy was different between both groups: there were more moderate and high risk for adverse pregnancy in patients with a history of pregnancy loss. Conclusion Patients with a history of pregnancy loss present delay to plan a new pregnancy, higher anti-DNA and antiphospholipid positivity. No worse pregnancy outcomes were observed. Disclosure of Interests None declaredTable 1Patients with previous abortion (n=13)Patients without previous abortions (n=28)P valueSociodemographic dataAge at visit (year)36.8±4.6134.4±3.930.43Age at diagnosis (year)28.31±2.4828.617±1.350.9Diagnosis-1st visit (years)8±6.716.93±5.50.58Last flare-1st visit (months)47±39.4527±38.590.049Immunological dataAnti-DNAds61.17±52.4642.62±52.460.043LA, n (%)11 (84.6)5 (17.9)0.004Anti-cardiolipin, n (%)9 (69.2)5 (17.9)0.003Ro52, n (%)3 (23.1)4 (14.3)0.49Ro60, n (%)1 (7.7)4 (14.3)0.55Diagnosis, n (%):-SLE6 (46.2)13 (46.4)0.99-APS1 (7.5)1 (3.57)0.58-Autoinflammatory03 (10.71)0.39-Other6 (46.2)11 (39.3)0.68Before preconception counselling0.39Treatment, n (%)-c/tsDMARD4 (30.8)7 (25)-HCQ3 (23.1)5 (7.9)-bDMARDs2 (15.4)9 (32)GC (n, %)7 (53.9)14 (49.9)0.82CYC (n, %)2 (15.4)3 (10.7)0.67After preconception counselling0.24Complications in pregnancy (n,%):-Medical2 (15.4)0-Obstetrical03 (10.7)Fertility assistance (n, %)0.73-AssistedNon-assisted011 (100)1 (8.3)11 (91.7)Abortion (n, %)1 (7.69)00.44

Background Little is known about the chronologic order of appearance of psoriasis (Pso) and psoriatic arthritis (PsA) symptoms and its effect on disease evolution. Most information is based on population-based registries or big data that may lack precision. Objectives To evaluate duration and chronologic order of appearance cutaneous and articular manifestations of PsA from 1st symptoms till diagnosis.To compare differences between patients with symptoms and diagnosis of Pso before PsA with those that manifest Pso after PsA. Methods A retrospective cohort study was conducted. Eligible patients were 219 patients that met ASAS criteria visited the SpA clinic between July – October 2022. Finally, 129 patients that met CASPAR criteria and Pso diagnosis were included. Other autoimmune rheumatic diseases were excluded. Data were collected previously reviewing patient records available from the electronic and paper database of the hospital. Additional information was retrieved by the shared medical history database of the Catalan Institute of Health which attends the 99.2% of the population. Missing data were collected prospectively by patient interview. ANOVA or Kruskall-Wallis test was carried out according to variable distribution. Results A total of 129 patients were included from which 98 had all time data related about disease appearance. There were 13.3% of missing data. The median disease evolution in years was 14 years with patients from 1 to 53 years of duration. The description and comparison of the clinical characteristics of each group is summarized in Table 1.Patients that begin with arthritis showed significant association with higher elevated C reactive protein and longer PsA disease duration. Longer time till arthritis appearance as well as more prevalence of Dactylitis was more observed in patients that begin with Pso before arthritis. Conclusion Significantly higher prevalence of CRP elevation in patients that begin with arthritis.Higher prevalence of dactylitis and longer time until articular manifestation was observed in patients that begin with Pso. Reference [1]J Am Acad Dermatol. 2019 Dec;81(6):1283-1291. Acknowledgements: NIL. Disclosure of Interests None Declared.SpA related variables, n (%)Pso before PsA (n=64)Same time (n=16)Pso after PsA (n=18)pMale36 (56.3)9 (56.3)10 (55.5)0.99HLAB27+12 (18.8)2 (12.5)1 (5.6)0.45Elevated CRP29 (45.3)11(68.8)14 (77.8)0.03Nail Pso40 (62.5)9 (56.3)12 (66.7)0.93Other Pso27 (42.2)8 (50%)15 (83.3)0.10Enthesitis27 (42.2)8 (50)7 (38.9)0.69Dactylitis25 (39.1)10 (62.5)3 (16.7)0.03Uveitis1 (1.6)01 (5.6)0.48Inflammatory bowel disease01 (6.25)1 (5.6)0.15Axial affection10 (15.6)2 (12.5)2 (11.1)0.80Family history of Pso29 (45.3)3 (18.8)7 (38.9)0.23Family history of SpA63 (98.4)14 (87.5)18 (100)0.04Time related variables, p50 (IQR)Age59.7 (15.4)58.5 (16.8)60.3 (19.6)0.38Years from 1st till 2nd manifestation24.5 (1)08 (9)0.00Years of delay until PsA diagnosis3 (0)1 (7)5.5 (8)0.07Years of disease duration11 (8)20 (18.5)19 (15)0.01

Background The ACR/EULAR group released the first-ever provisional classification criteria for calcium pyrophosphate deposition disease (CPPD) at the ACR congress in November 2022. These criteria are based on an adjusted domain scoring system including demographic, clinical and radiological characteristics, and synovial fluid crystal analysis. The differential diagnosis in CPPD must be made with rheumatoid arthritis (RA) and monosodium urate crystal deposition disease. Objectives To study the percentage of patients diagnosed with seronegative RA who meet the new 2022 ACR/EULAR classification criteria for CPPD (final score ≥57). To determine the clinical and demographic differences between patients with a diagnosis of seronegative RA who meet or not the classification criteria for CPPD. Methods An observational retrospective cross-sectional study was performed including all the patients from a monographic RA clinic between September and December 2022. Demographic, clinical, analytical and imaging variables (simple radiology and ultrasound) were collected. The 2022 ACR/EULAR provisional classification criteria for CPPD were applied. Results Overall, 364 patients with RA were identified and those with seropositivity for RF and/or ACPAs were excluded. A total of 96 (24.4%) patients were included, 74.7% females, with a mean age at onset of symptoms of 59.3 (±16.4) years and 8.35 years of disease duration. A total of 18 patients (18.9%) met the classification criteria for CPPD. The characteristics and differences between the patients who met or not the criteria are shown in Table 1. The patients who met the CPPD criteria were older (p=0.048) and had a different clinical presentation (p=0.010) relating to the time-course of inflammatory arthritis (persistent, 1 typical episode, >1 typical episode, others). No significant differences were observed between groups in the location of joint clinical involvement. There was a statistically significant association (p=0.000) between the presence of radiological chondrocalcinosis (CC) and the fulfillment of criteria for CPPD, being detected in 66.6% of patients with CPPD versus none with seronegative RA without CPPD. Similarly, there was a significant association (p=0.000) between osteoarthritis in typical locations for CPPD (bilateral radiocarpal, scaphoid/trapezium/trapezoid without rhizarthrosis, 2nd and 3rd MCF) and compliance with criteria for CPPD, being detected in 55.5% of patients with CPPD. A higher prevalence of erosions was detected in patients with CPPD (44.4%) versus seronegative RA without CPPD (27.3%), without statistical significance. No significant treatment differences were observed in both subgroups. Of the patients with criteria for CPPD, 74% were being treated with synthetic of biological disease modifying antirheumatic drugs (DMARDs). Conclusion A total of 18 (18.9%) patients with seronegative RA from a monographic RA unit met the new 2022 ACR/EULAR provisional classification criteria for CPPD. Age at diagnosis and clinical presentation were different between patients with RA who met criteria for CPPD and those who did not. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests None Declared.Table 1Characteristics of the sample according to the fullfilment or not of the new 2022 ACR/EULAR classification criteria for CPPD.Total (n=95)Seronegative RA with CPPD* (n=18)Seronegative RA without CPPD (n=77)pFemale gender, n (%)71 (74.7%)16 (88.8%)55 (71.4%)0.142Age at onset (years), p506369.5610.048Disease duration (years), p507670.952Time-course, n (%)0.010- Persistent arthritis38 (40%)4 (21.1%)34 (44.5%)- 1 typical episode0 (0%)0 (0%)0 (0%)- >1 typical episode39 (41.1%)13 (72.2%)26 (33.8%)- Others18 (18.8%1 (5.3%)17 (22.1%)Erosions, n (%)29 (30.5%)8 (44.4%)21 (27.3%)0.091Treatment, n (%)0.854Prednisone21 (21.9%)4 (21.1%)17 (22.1%)sDMARD45 (46.9%)10 (52.6%)35 (45.5%)bDMARD19 (20%3 (16.6%)4 (20.8%)Combination therapy10 (10.4%)1 (5.3%)9 (11.7%)

Background Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired muscle diseases with distinct clinical, pathological and histological features. interstitial lung disease (ILD) is a frequent pulmonary manifestation in IIM (IIM-ILD) and considerably influences morbidity and mortality. Krebs von den Lungen 6 (sKL-6) has been proposed as a potential biomarker reflecting the severity of ILD in connective tissue diseases. Raynaud’s phenomenon is very frequent and the presence of microvascular changes in IIM have been described however, the role of nailfold videocapillaroscopy (NVC) in diagnosis and prognosis in IIM is not clearly established. Objectives To determine if there is any association between NVC findings, sKL-6 levels and pulmonary involvement in patients with inflammatory myopathies. Methods We performed a retrospective study of IIM patients followed in a reference center and compared them according to the presence of ILD. Epidemiological, clinical and immunological data, pulmonary function tests (forced vital capacity and diffusing capacity for carbon monoxide), sKL-6 levels and NVC finding were retrieved. NVC findings including loss of capillary density, enlarged and giant capillaries, ramified capillaries, haemorrhages, thrombosis, avascular areas, disorganization of capillary architecture and subpapillary venous plexus presence were recollected, if present. Statistical analysis was performed by T-test and Fisher’s exact test to compare qualitative and/or quantitative variables and multiple logistic regression modelling to identify correlation between pulmonary function tests, NVC findings and sKL-6 levels. Values of p<0.05 were considered statistically significant. Results 95 patients were included, 47 patients (49%) with ILD. 34% were male with a median age at inclusion of 55.3±24 years and a median disease duration of 6.8±7 years. Avascular areas and capillary loss showed a significant association with the presence of ILD (OR 2.43, 95% CI 1.3-5.7, p 0.004) and (OR 1.7, 95% CI 1.48-3.1, p 0.04). A negative correlation between capillary loss and enlarged capillaries was also found with FVC% (β=-0.46, p 0.001 and β=-0.57, p <0.0001) and DLCO% (β=-0.32, p 0.04 and β=-0.23, p 0.03), respectively. When we studied the correlation between sKL-6 levels, positive correlations with the presence of ILD (β=0.77, p 0.0004), the presence of hemorrhages (β =0.21, p 0.04) and avascular areas in NVC (β =0.64, p 0.03) and negative correlations with FVC% (β=-0.47, p 0.001) and DLCO% (β=-0.59, p, 0.005) were found. Multiple logistic regression identified as predictors for developing IIM-ILD are summarized in Table 1 and represented in the scatter plot in Figure 1. Male sex, respiratory symptoms, %FVC and %DLCO, sKL-6 levels, anti-Jo1 positivity and the presence of avascular areas and enlarged capillaries in NVC were identified as IIM-ILD predictors (R²=0.974, p =0.006). Conclusion Capillary loss and avascular areas showed a significant association with the presence of ILD, worse FVC and DLCO values and sKL-6 levels. We identified 9 predictors for developing ILD in IIM. NVC assessment and sKL-6 levels can have a predictive role for studying pulmonary function and assessing the prognosis of IIM-ILD. Reference [1]Castellví I, Simeón-Aznar CP, Sarmiento M, Fortuna A, Mayos M, Geli C, Diaz-Torné C, Moya P, De Llobet JM, Casademont J. Association between nailfold capillaroscopy findings and pulmonary function tests in patients with systemic sclerosis. J Rheumatol. 2015 Feb;42(2):222-7. doi: 10.3899/jrheum.140276. Epub 2014 Nov 15. PMID: 25399393. Acknowledgements: NIL. Disclosure of Interests None Declared.